C
26.08
1.13 (4.53%)
| 前收盘价格 | 24.95 |
| 收盘价格 | 24.70 |
| 成交量 | 611,525 |
| 平均成交量 (3个月) | 1,244,193 |
| 市值 | 1,987,955,712 |
| 价格/销量 (P/S) | 3.51 |
| 股市价格/股市净资产 (P/B) | 3.05 |
| 52周波幅 | |
| 利润日期 | 7 Aug 2025 |
| 营业利益率 (TTM) | -81,161.54% |
| 稀释每股收益 (EPS TTM) | -1.50 |
| 季度收入增长率 (YOY) | -90.20% |
| 总债务/股东权益 (D/E MRQ) | 0.15% |
| 流动比率 (MRQ) | 30.97 |
| 营业现金流 (OCF TTM) | -81.98 M |
| 杠杆自由现金流 (LFCF TTM) | -57.18 M |
| 资产报酬率 (ROA TTM) | -12.85% |
| 股东权益报酬率 (ROE TTM) | -16.58% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | CG Oncology, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
1.6
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.63 |
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 1.17% |
| 机构持股比例 | 105.34% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 56.00 (Morgan Stanley, 114.72%) | 购买 |
| 中 | 55.00 (110.89%) | |
| 低 | 53.00 (RBC Capital, 103.22%) | 购买 |
| 平均值 | 54.67 (109.62%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 25.96 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Piper Sandler | 19 Aug 2025 | 55.00 (110.89%) | 购买 | 25.56 |
| RBC Capital | 16 Jul 2025 | 53.00 (103.22%) | 购买 | 26.08 |
| Morgan Stanley | 17 Jun 2025 | 56.00 (114.72%) | 购买 | 26.24 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合